PHA Pharmagest Interactive SA

EQUASENS GROUP: H1 2023 revenue: up 9% to €112.62m

EQUASENS GROUP: H1 2023 revenue: up 9% to €112.62m

Villers-lès-Nancy, 3 August 2023 - 6:00 p.m. (CET)


H1 2023 revenue:

up 9% to €112.62m

  • Growth by all Divisions, with the exception of FINTECH, which nonetheless benefited from an upturn in Q2.
  • Effects of the French Digital Healthcare investment programme (Ségur du Numérique en Santé)
    • The Group is continuing to install solutions qualifying for the Ségur French Digital Healthcare investment programme: €2m at 30 June 2023.
    • Sales revenues from the recurring portion of the Ségur programme: €0.6m.
(€m) H1 2022H1 2023Change

2023 / 2022
Q149.3656.25 +14% (*)
Q254.2156.37 +4%
H1 103.57112.62 9%

(*) Strong growth in Q1 reflecting a favourable comparison base (restructuring of the electronic labelling activity).

As a reminder, to streamline business operations, organisational changes were implemented in H1 involving business transfers between Divisions:

  • After buying out the minority interests, MULTIMEDS (Ireland) and I-MEDS (Germany) were transferred to the PHARMAGEST Division (Compliance segment) and CAREMEDS (United Kingdom) joined the AXIGATE LINK Division (Nursing Home segment);
  • The ICT company developing MEDILINK, a solution for health centres and regional health professional communities, has joined forces with the MEDICAL SOLUTIONS Division to expand PROKOV EDITIONS' range.

Plus recent acquisitions:

  • ATOOPHARM joined the PHARMAGEST Division,
  • SPEECH2SENSE and PRATILOG are now part of the MEDICAL SOLUTIONS Division.

Consolidated for the first time in Q2, revenue generated by these entities was not material at 30 June 2023.

H1 2023 business highlights

  • The PHARMAGEST Division  reported sales of €83.7m, up 9% from H1 2022
    • While growth by the PHARMAGEST Division was more subdued in Q2, revenue remained strong at €83.7m at 30 June 2023, up from €76.7m in 2022.
    • The growth drivers remained unchanged, with strong momentum in the electronic labelling market and, in Italy, new pharmacy software solutions.
    • This Division accounted for 74% of Equasens Group's total revenue.
  • The AXIGATE LINK Division recorded revenue of €14.9m, up 6% from H1 2022, driven in particular by the long-standing Nursing Homes and Home Hospital business.
    • This Division accounted for 13% of Equasens Group's total revenue.
  • The E-CONNECT Division had revenue of €8.1m, up 10% from H1 2022.
    • Q2’s excellent performance (+17% to €4.1m) confirmed the benefits of the new industrial strategy of diversifying production sourcing enabling the Division to respond more rapidly to market needs.
    • This Division accounted for 7% of Equasens Group's total revenue.

  • The MEDICAL SOLUTIONS Division reported revenue of €4.9m, up 13% on H1 2022 largely in response to the success of the latest version of the MédiStory software.

    • This Division accounted for 4% of Equasens Group's total revenue.
  • The FINTECH Division had revenue of €1.1m, down 3% from H1 2022.
    • The financing brokerage activity continues to be impacted by high interest rates. Despite this, the Division has adapted its strategy by targeting more promising growth markets contributing to a return to growth in Q2.
    • This Division accounted for 1% of Equasens Group's total revenue.

2023 outlook

  • Continuing growth in H2 2023, with the launch of new products (mobility, security, SaaS offerings, etc.) boosting sales across all business segments.
  • Confirmation of the business upturn for the FINTECH Division.
  • The ongoing integration of recent acquisitions expected to enhance the Group's technology offering and accelerate growth.
  • Backed by the financial resources to pursue external growth opportunities, the Group will remain attentive to potential acquisitions.

Financial calendar

  • Publication H1 2023 results: 29 September 2023 (after the close of trading).
  • H1 2023 results information meeting: 2 October 2023 (by videoconference).
  • Publication of Q3 2023 revenue: 9 November 2023 (after the close of trading).


Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "more technology for more humanity", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.

Listed on Euronext Paris™ - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid-caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group and on


Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT

Tel. +33 (0)3 83 15 90 67 -

Media Relations:


Tel. +33 (0)6 17 38 61 78 -   




To request access to management, click here to engage with our
partner Phoenix-IR's

Reports on Pharmagest Interactive SA

Arnaud Riverain
  • Arnaud Riverain

EQUASENS: Acquisition of the German company ADV and creation of PHARMA...

EQUASENS: Acquisition of the German company ADV and creation of PHARMAGEST Germany Villers-lès-Nancy, 23 November 2023 - 6:00 p.m. (CET) PRESS RELEASE Acquisition of the German company ADVand creation of PHARMAGEST Germany EQUASENS, in partnership with ARZ HAAN, a German market leader for services and software solutions for healthcare providers, acquires ADV (Apotheken Datenverarbeitung GmbH & Co. KG), which becomes PHARMAGEST Germany, through a holding company 6%-held by ARZ HAAN and 94%-held by EQUASENS. PHARMAGEST Germany will invest in developing technology and technical building bl...


EQUASENS : Acquisition de l’allemand ADV et naissance de PHARMAGEST Ge...

EQUASENS : Acquisition de l’allemand ADV et naissance de PHARMAGEST Germany Villers-lès-Nancy, le 23 novembre 2023 – 18:00 (CET) COMMUNIQUE DE PRESSE Acquisition de l’allemand ADV et naissance de PHARMAGEST Germany EQUASENS, en association avec ARZ HAAN, un des leaders sur le marché de la Santé en Allemagne, acquiert au travers d’une Holding détenue à 6% par ARZ HAAN et 94% par EQUASENS, la société allemande ADV (Apotheken Datenverarbeitung GmbH & Co. KG) qui devient PHARMAGEST Germany. PHARMAGEST Germany investira dans le développement de briques technologiques et techniques ainsi que ...

Arnaud Riverain
  • Arnaud Riverain

EQUASENS - CA T3 : Le Ségur perturbe le marché / Achat - Obj. 94,6 € -...

CA T3 stable à 50,1 M€                          / 9 mois +6% à 153,7 M€. Pharmagest T3 -1% (36,8 M€)      / 9 mois +6% ; Axigate Link T3 +6% (7,4 M€)      / 9 mois +6% ; E-Connect T3 +23% (3,6 M€)       / 9 mois +13% ; Medical Solutions -24% (1,8 M€)   / 9 mois +0%; Acquisition à venir d’ici la fin de l’année.


Equasens: Q3 2023 revenue

Equasens: Q3 2023 revenue Villers-lès-Nancy, 9 November 2023 - 6:00 p.m. (CET) PRESS RELEASE Q3 2023 revenue Q3 2023 revenue: stable year-on-year at €50.1mGrowth impacted by: The completed deployment of solutions under the Ségur French Digital Healthcare investment programme:Adverse market conditions affecting Pharmacy sector. In €m20222023Change2023 / 2022Q149.456.3+14% (*)Q2 54.256.3 4 %Q3 (unaudited) 50.1 50.10 %9 month YTD 153.7162.7 6 % (*) Strong growth in Q1 reflecting a favourable comparison base (restructuring of the electronic labelling activity). ____________ : The PHARM...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch